GeNeuro SA

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical tr…

Biotechnology

CH, Plan-les-Ouates [HQ]

Major Shareholders · Proxy Ben. Owners

Shareholders

Major Shareholders · Outstanding & Floating

Breakdown

The breakdown presents the total weighting of the relevant parties: Institutes, Insiders & Public. It's perfect to get a quick briefing regarding the shareholder structure of GeNeuro SA

GeNeuro SA can't present any analysts estimates at the moment detail analysis.

Beneficial Owners Beta

Beneficial owners hold at least 10% of the stocks outstanding. Palmy retrieves this information from the most reliable, audited format which presents the data, the proxy statement.

Soon Available - Stay Tuned